XYNAPSE Trademark
Trademark Overview
On Thursday, October 16, 2025, a trademark application was filed for XYNAPSE with the United States Patent and Trademark Office. The USPTO has given the XYNAPSE trademark a serial number of 99446868. The federal status of this trademark filing is APPROVED FOR PUBLICATION as of Friday, May 29, 2026. This trademark is owned by Immudex ApS. The XYNAPSE trademark is filed in the Chemical Products and Pharmaceutical Products categories with the following description:
Chemical products for diagnostic, industrial and scientific purposes, namely reagents and assays for activation, stimulation and proliferation of immune cells T cells and B cells, other than for medical or veterinary use; Diagnostic reagents for diagnostic and scientific purposes, other than for medical or veterinary use; Research reagents for scientific and diagnostic purposes, other than for medical or veterinary use; Diagnostic test materials in the nature of reagents and assays for scientific and diagnostic purposes, other than for medical or veterinary use; Diagnostic kits comprising diagnostic agents, preparations and substances for scientific and diagnostic purposes, other than for medical or veterinary use; Assays for research and diagnostic purposes, other than for medical or veterinary use; Biochemical reagents, other than for medical or veterinary use; Analytical preparations in the nature of reagents and assays for scientific purposes related to research and development of ...
Preparations for pharmaceutical purposes, for the treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; Preparations for medical purposes, namely, diagnostic preparations for medical purposes and medical preparations for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; Chemical-pharmaceutical preparations for the treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; Diagnostic preparations for medical purposes; Reagents for medical and veterinary purpose...
General Information
| Serial Number | 99446868 |
| Word Mark | XYNAPSE |
| Filing Date | Thursday, October 16, 2025 |
| Status | 680 - APPROVED FOR PUBLICATION |
| Status Date | Friday, May 29, 2026 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Translation of Words in Mark | The English translation of "Xynapse" in the mark is "wake up". |
| Goods and Services | Chemical products for diagnostic, industrial and scientific purposes, namely reagents and assays for activation, stimulation and proliferation of immune cells T cells and B cells, other than for medical or veterinary use; Diagnostic reagents for diagnostic and scientific purposes, other than for medical or veterinary use; Research reagents for scientific and diagnostic purposes, other than for medical or veterinary use; Diagnostic test materials in the nature of reagents and assays for scientific and diagnostic purposes, other than for medical or veterinary use; Diagnostic kits comprising diagnostic agents, preparations and substances for scientific and diagnostic purposes, other than for medical or veterinary use; Assays for research and diagnostic purposes, other than for medical or veterinary use; Biochemical reagents, other than for medical or veterinary use; Analytical preparations in the nature of reagents and assays for scientific purposes related to research and development of vaccines and immunotherapeutics, cancer vaccines, borrelia vaccines, tuberculosis vaccines, HIV vaccines, CMV vaccines and other vaccines, or for use in connection with research and development of drug therapy and immunotherapy, including cancer therapy, cancer immunotherapy, for scientific analysis of pharmaceuticals for T-cell lymphoma, T-cell infiltration of solid tumors and tissues, and for analysis of pharmaceuticals infectious diseases and autoimmunity, and for scientific and research use in connection with toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring, other than for medical or veterinary use; Chemical reagents for diagnostic, industrial and scientific purposes |
| Goods and Services | Preparations for pharmaceutical purposes, for the treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; Preparations for medical purposes, namely, diagnostic preparations for medical purposes and medical preparations for treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; Chemical-pharmaceutical preparations for the treatment of cancer, T-cell lymphoma, T-cell infiltration of solid tumors and tissue, T-cell diseases in blood, transplantation related diseases and diseases related to immune suppression, autoimmune disease and infectious diseases; Diagnostic preparations for medical purposes; Reagents for medical and veterinary purposes; Vaccines; Analytical preparations in the nature of assays and reagents for medical purposes, including for the medical or diagnostic analysis of vaccines, immunotherapeutics and cellular therapy, including cancer vaccines and immunotherapeutics, borrelia vaccines, tuberculosis vaccines, HIV vaccines and CMV vaccines, T-cell treatments, or for use in connection with cancer therapy or other therapy, for the diagnosis or treatment of T-cell lymphoma, T-cell infiltration of solid tumors and tissues, and infectious diseases, and for use in connection with medical or diagnostic analysis of toxicological studies, transplantation, immune monitoring, or vaccines and T-cell monitoring |
Classification Information
| International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
| US Class Codes | 001, 005, 006, 010, 026, 046 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, October 16, 2025 |
| Primary Code | 001 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, October 16, 2025 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | Immudex ApS |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 24 - NOT AVAILABLE |
| Address | Virum DK-2830
DK |
Trademark Events
| Event Date | Event Description |
| Thursday, October 16, 2025 | NEW APPLICATION ENTERED |
| Thursday, October 16, 2025 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, October 16, 2025 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, March 4, 2026 | ASSIGNED TO EXAMINER |
| Wednesday, March 11, 2026 | NON-FINAL ACTION WRITTEN |
| Wednesday, March 11, 2026 | NON-FINAL ACTION E-MAILED |
| Wednesday, March 11, 2026 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Thursday, May 28, 2026 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Thursday, May 28, 2026 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, May 28, 2026 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, May 29, 2026 | APPROVED FOR PUB - PRINCIPAL REGISTER |
